The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Jounce Therapeutics Inc. (JNCE) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $1.08. The Jounce Therapeutics Inc. has recorded 4,861 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics.
Jounce Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.08 and fluctuated between $1.2100 as its day high and $1.0700 as its day low. The current market capitalization of Jounce Therapeutics Inc. is $56.72M. A total of 0.72 million shares were traded on the day, compared to an average of 1.58M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, JNCE has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 5 BUYs and 0 SELLs from insiders. Insiders purchased 205,000 shares during that period but sold 0.
In the most recent transaction, Cole Hugh M sold 9,182 shares of JNCE for 1.12 per share on Jan 10. After the transaction, the Chief Operating Officer now owns 110,082 company shares. In a previous transaction on Jan 10, Drapkin Kimberlee C sold 7,781 shares at 1.12 per share. JNCE shares that CFO and Treasurer owns now total 66,018.
Among the insiders who sold shares, MURRAY RICHARD /CA/ disposed of 24,879 shares on Jan 10 at a per-share price of $1.12. This resulted in the CEO and President holding 228,007 shares of JNCE after the transaction. In another insider transaction, Trehu Elizabeth sold 5,126 shares at $1.12 per share on Jan 10. Company shares held by the Chief Medical Officer now total 103,417.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for JNCE in the last 3 months, the mean price target is $6.00 with high estimates of $11.00 and low estimates of $3.00. In terms of 52-week highs and lows, JNCE has a high of $8.80 and a low of $0.58.
As of this writing, JNCE has an earnings estimate of -$0.64 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.6 per share and a lower estimate of -$0.68. The company reported an EPS of -$0.72 in the last quarter, which was -26.30% lower than expectations of -$0.57.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JNCE is Overweight with a score of 4.50. A total of 4 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.